Introduction
Combination antiretroviral therapy is capable of controlling HIV-1 replication in many HIV-1-infected individuals. [1] [2] [3] [4] [5] [6] However, several studies have shown that HIV-1 persists in latently infected cells in well-controlled individuals. [1] [2] [3] [4] [5] [6] Discontinuation of antiretroviral therapy in such individuals could allow reactivation of HIV-1 from latently infected cells and renewed active replication. [4] [5] [6] Recent studies have provided strong evidence that HIV-1 establishes a state of latent infection in resting memory CD4
+ T cells in vivo. [6] [7] [8] As an alternative to longterm antiretroviral therapy, gene therapy might be used to prevent reactivation from latently infected cells. Gene therapy for AIDS is an approach in which genes that are capable of blocking productive HIV replication are introduced into cells that are potential sites for viral replication. [9] [10] [11] [12] Both RNA-and protein-based gene therapy strategies have been used to inhibit HIV-1 replication. Among the potential genetic targets for intervention in HIV life cycle, the tat gene product is a key target.
was demonstrated in antitat gene-transduced U1 and ACH-2 cells maintained in G418-free media for 5 months, suggesting that functional antitat gene may persist for many months in transduced cells and their progeny. Most importantly, we demonstrate that the antitat gene, when introduced into peripheral blood mononuclear cells (PBMC) isolated from patients with HIV-1 infection, inhibited TNF-␣ plus PMA-induced viral replication as determined by RT-PCR and RT activity. In addition, the antitat gene enhanced the survival of CD4 + T lymphocytes from such patients. These data suggest the feasibility of utilizing antitat gene therapy to block activation and replication of HIV-1 in latently infected monocytes and T-lymphocytes in vivo. Gene Therapy (2000) 7, 321-328.
Tat is an early transactivator of the expression of all HIV genes following specific interaction with the tat activation response element (TAR) sequence located at the 5′ end of all viral RNAs. [13] [14] [15] Tat also plays an important role in the pathogenesis of AIDS as an activator of the expression of inflammatory cytokines, some of which promote HIV replication themselves. 16, 17 Thus, Tat is essential for HIV-1 replication and important for transition from latent to productive infection. We recently demonstrated that an autoregulated dual-function antitat gene blocked HIV-1 replication in human peripheral blood mononuclear cells (PBMC) 15 and CD34 + hematopoietic progenitor cells. 18 This antitat gene has several important features relevant to its therapeutic potential. [13] [14] [15] First, its expression is dependent on activation by Tat, and therefore the antitat gene should be expressed only in cells in which Tat protein is present. Antitat is not only regulated by Tat but also inhibits Tat, which provides a mechanism for modifying the response to Tat. Antitat is not produced in cells in which it is not needed, ie in uninfected cells. [13] [14] [15] Second, antitat is a dual-function gene, inhibiting HIV-1 Tat through two different mechanisms (sequestering Tat protein and blocking its translation from mRNA). Third, since it is an RNA-based approach, use of an antitat gene is unlikely to induce host immune responses that might serve to eliminate cells expressing a foreign protein. Anti-tat ultimately decreases the amount of Tat protein by inhibiting the translation of tat messenger RNA and also by blocking activation of HIV-1 RNA synthesis by Tat.
Although antitat gene has been tested for its ability to inhibit HIV-1 replication in human peripheral blood mononuclear cells as well as in CD34
+ hematopoietic cell derived T-lymphocytes and macrophages, 18 little information is available on its effects in cells latently infected with HIV-1.
Important cellular sites for latent HIV-1 infection include CD4
+ T-lymphocytes and macrophages. 19 The cellular and molecular mechanisms of activation of latently integrated HIV-1 provirus in promonocytic (U1) and T-lymphocytes (ACH-2) cells have been well-delineated. [20] [21] [22] [23] These cell lines have been studied extensively as in vitro models for viral latency. 23 Studies of U1 and ACH-2 have provided substantial information about the stimuli and regulatory pathways that may be involved in the activation of HIV replication in vivo 23 HIV-1 activation and replication in these cells, and presumably others are under the control of the endogenous cytokine network. 24, 25 Cytokines act as physiologic inductive signals in regulation of immune responses. One cytokine, tumor necrosis factor-alpha (TNF-␣), up-regulates HIV-1 replication in both U1 and ACH-2 cells. 24, 25 Phorbol 12-myristate 13-acetate (PMA) stimulation of U1 and ACH-2 cells not only induces HIV-1 production, but also induces terminal differentiation of these cells along the mononuclear phagocytic lineage with appearance of HIV-1 particles in Golgi-derived intracellular vacuoles, as described in primary infected macrophages. In order to evaluate the ability of gene therapy to block activation of HIV from latent viral reservoirs, antitat gene was tested for its effect on HIV-1 replication in chronically infected monocytes and lymphocytes. Specifically, we investigated whether intracellular expression of antitat gene in U1 and ACH-2 cell lines affects HIV-1 activation and replication induced by TNF-␣ plus PMA. In addition, we tested whether antitat gene can block replication of HIV in PBMC isolated from patients with HIV-1 infection.
Results
Expression of neo-R gene in antitat and control vectortransduced U1 and ACH-2 cells In order to confirm the presence of retroviral vectors in transduced and G-418 selected U1 and ACH-2 cells, we used RT-PCR to determine whether the transduced cells expressed mRNA from the neomycin resistance (neo-R) gene that is used as a selectable marker gene in both the antitat and the control vectors. Figure 1 shows that under the experimental conditions used, neo-R mRNA expression was detected in both the antitat retroviral vector and the control vector transduced-U1 and ACH-2 cells as analyzed by RT-PCR. The percentage of transduced U1 and ACH-2 cells was estimated before and after G418 selection by PCR with primers targeting the neo-R gene. The transduction efficiency was between 20% and 30% before selection, whereas G418 selection significantly increased the efficiency up to about 80% (Figure 2 ).
Inhibition of TNF-␣ plus PMA-induced HIV-1 gag gene expression by antitat
In order to determine the effect of antitat gene on HIV-1 mRNA expression, antitat or control vector transduced 
Figure 4 Effect of antitat gene on TNF-␣ plus PMA-induced HIV-1 replication in latently infected U1 and ACH-2 cells. Antitat retroviral vectortransduced and G-418 selected U1 and ACH-2 cells (U1 antitat and ACH-2 antitat) were incubated with TNF-␣ (2 ng/ml) plus PMA (2 ng/ml). Controls include control vector-transduced and G-418 selected U1 and ACH-2 cells (U1 control and ACH-2 control), as well as nontransduced U1 and ACH-2 cells (U1 and ACH-2) incubated with or without TNF-␣ plus PMA as indicated. Culture supernatants were collected for HIV-1 RT activity assay 72 h after induction with TNF-␣ plus PMA.
and G-418 selected-U1 and ACH-2 cells were incubated with TNF-␣ plus PMA and then subjected to RNA extraction and RT-PCR using a specific primer pair for HIV-1 gag gene. As shown in Figure 3 , antitat gene inhibited expression of HIV-1 gag gene mRNA compared with control vector-transduced U1 and ACH-2 cells.
Figure 5 Effect of antitat gene on TNF-␣ plus PMA-induced HIV-1 replication in U1 and ACH-2 cells at different time-points. Antitat retroviral vector-transduced and G-418 selected U1 or ACH-2 cells (U1 or ACH-2 antitat) were incubated with TNF-␣ (2 ng/ml) plus PMA (2 ng/ml). Controls include control vector-transduced U1 or ACH-2 cells (U1 or ACH-2 control) and non-transduced U1 or ACH-2 cells (U1 or ACH-2) incubated with or without TNF-␣ plus PMA as indicated. Culture supernatants were collected for HIV-1 RT activity assay at 2, 4 and 6 days after induction. (a) U1; (b) ACH-2.
Gene Therapy Inhibition of TNF-␣ plus PMA-induced HIV-1 replication by antitat in U1 and ACH-2 cells To evaluate the effect of intracellular antitat expression on TNF-␣ plus PMA-induced HIV-1 replication, U1 and ACH-2 cells were transduced with either antitat retroviral vector or control vector, selected in G418-containing medium for 2 weeks and then incubated with TNF-␣ plus PMA. As expected, TNF-␣ plus PMA induced HIV-1 replication in non-transduced and control vector-transduced U1 and ACH-2 cells (Figure 4) . In contrast, TNF-␣ plus PMA-induced HIV-1 replication was significantly reduced (P Ͻ 0.01) in U1 and ACH-2 cells transduced with the antitat retroviral vector (Figure 4) .
Stability of antitat gene expression in U1 and ACH-2 cells
To determine the stability of antitat gene in transduced U1 and ACH-2 cells, we analyzed HIV-1 RT activity in these cells at multiple time-points (2, 4 and 6 days) after TNF-␣ plus PMA induction. As shown in Figure 5 , differences in RT activity among the non-transduced, control vector-transduced and antitat retroviral vector-transduced U1 and ACH-2 cells were similar across these time-points. In non-transduced U1 and ACH-2 cells, as well as control vector-transduced U1 and ACH-2 cells, TNF-␣ plus PMA dramatically induced HIV-1 replication, while HIV replication was significantly lower (P Ͻ 0.01) in antitat retroviral vector-transduced U1 and ACH-2 cells.
Anti-HIV effect of antitat in long-term cultured U1 and ACH-2 cells
In order to determine the stability of anti-HIV activity in antitat-transduced U1 and ACH-2 cells, antitat-transduced and control vector-transduced U1 and ACH-2 cells were maintained in G418-free media for 5 months. The cells were then incubated with TNF-␣ plus PMA. TNF-␣ plus PMA-induced HIV-1 replication was still significantly inhibited in antitat retroviral vector-transduced U1 and ACH-2 cells maintained in G418-free cultures for 5
Figure 6 Effect of antitat gene on HIV-1 replication in long-term cultured U1 and ACH-2 cells. Antitat retroviral vector or control vector-transduced U1 (U1 antitat) or ACH-2 (ACH-2 antitat) were maintained in G418-free cultures (split every 3 days) for 5 months. The cells were then stimulated with TNF-␣ (2 ng/ml) plus PMA (2 ng/ml). Controls include control vector-transduced U1 and ACH-2 cells (U1 control and ACH-2 control), as well as non-transduced U1 and ACH-2 cells (U1 and ACH-2) incubated with or without TNF-␣ plus PMA as indicated. Culture supernatants were collected for HIV-1 RT activity assay 72 h after induction.
months compared with control vector-transduced cells cultured under identical conditions ( Figure 6 ).
Anti-HIV effect of antitat in primary human lymphocytes
We investigated whether antitat gene, when introduced into PBMC isolated from patients with HIV-1 infection, inhibits HIV-1 activation and replication. PBMC isolated from the individuals with HIV-1 infection were transduced with either antitat vector or control vector, and then activated with TNF-␣ plus PMA. Antitat inhibited TNF-␣ plus PMA induced-HIV-1 replication in these primary cells in a manner similar to the inhibition observed in U1 and ACH-2 cell lines. As demonstrated in Figure 7 , TNF-␣ plus PMA-induced HIV-1 gag gene expression was lower in antitat gene transduced PBMC compared with control vector-transduced PBMC. In addition, antitat vector-transduced CD4 + T lymphocytes had a survival advantage. After incubation with TNF-␣ plus PMA for 14 days, the percentage of CD4
+ lymphocytes was significantly higher in antitat-transduced PBMC cultures than in control vector-transduced PBMC cultures (Figure 8 ). These data indicate that antitat gene therapy not only inhibits HIV-1 replication and hinders virus spread but also may prevent death of CD4 + lymphocytes.
Discussion
Recent studies have documented the existence of latently infected CD4 + cells in HIV-infected individuals receiving highly active antiretroviral therapy. [6] [7] [8] The decay rate for such cells appears to be very slow, suggesting that antiretroviral therapy alone will not lead to eradication of this reservoir. 6 If this is case, HIV-infected individuals may have to be maintained on antiretroviral drugs for life. Such prolonged therapy may be difficult to maintain owing to toxicities associated with antiretroviral drugs and other factors that affect long-term compliance. Alternative or complementary approaches towards control of latent HIV infection are being considered. One approach would be to induce HIV-specific cellular immune responses by immunization with candidate HIV vaccines, since such responses are thought to contribute to control of HIV replication during early, and possibly other stages of HIV infection and frequently are not detectable in HIV-infected individuals receiving highly active antiretroviral therapy. Alternatively, as explored in the current
Figure 8 Protection of CD4 + T lymphocytes from cytopathic effect of HIV-1 by antitat gene. Control and antitat retroviral vector-transduced PBMC isolated from three patients (P1, P2 and P3) were incubated with TNF-␣ (2 ng/ml) plus PMA (2 ng/ml). At day 14 after incubation with TNF-␣ plus PMA, CD4
+ T lymphocytes were analyzed by flow cytometric assay using anti-CD4 antibody. study, gene therapy might be used to maintain HIV in a dormant state in latently infected cells.
We recently demonstrated that cytokine-induced HIV-1 replication in chronically infected monocytes and lymphocytes is inhibited by retrovirus-mediated gene transfer of anti-Rev single chain variable fragments. 26 In the experiments described in this study, we explored the possibility that another approach, namely antitat gene therapy, could be used to maintain HIV-1 in a latent state, in the absence of antiretroviral agents. With the antitat gene used in these experiments, HIV-1 gene expression is inhibited by two mechanisms (Figure 9 ): polymeric TAR RNA can bind and sequester Tat protein in the nucleus, and antisense-tat RNA can inhibit translation of tat mRNA in the cytoplasma. [13] [14] [15] In uninfected cells antitat gene transcription is minimal, as HIV-1 LTR (which is the promoter for the antitat gene) is inactive in the absence of Tat protein.
14,15 Therefore, it is conceivable that antitat gene does not interfere with cellular gene regulation or cause toxicity due to overexpression of antiviral RNA. Normal T cells transduced by the antitat are indistinguishable from control vector-transduced cells.
14 In addition, since its mechanism of action involves RNA, the antitat gene is unlikely to serve as a target for host immune responses that might serve to eliminate cells expressing a foreign protein. 15 The U1 and ACH-2 cell lines have provided useful models for investigating the mechanisms of proviral latency and activation. 23 Saksela et al 27 demonstrated that unstimulated peripheral blood mononuclear cells from HIV-1 infected chimpanzees did not show any detectable signs of viral replication yet can be rapidly induced to express viral mRNAs after exposure to PMA-PHA in vitro. A recent study showed that combination of the proinflammatory cytokines TNF-␣ and IL-6 together with IL-2, potently induced HIV-1 replication in latently infected, resting CD4
+ T cells derived from HIV-infected individuals who are under highly active antiviral therapy. 28 Thus, it is possible that the mechanisms of latency in U1 15 The
Figure 9 Protection of latently infected cells by antitat gene therapy. Antitat gene combines two inhibitory molecules: polymeric-TAR and antisensetat.

combination leads to additive inhibition of Tat function and HIV-1 gene expression. During successful antiretroviral therapy the latently infected cells are the major viral reservoirs. These cells contain proviruses, which do not produce HIV. However, in response to antigens or cytokines these cells are activated resulting in high levels of gene expression and virus production. Antitat gene therapy can keep HIV in these cells in the latent stage by inhibition of Tat-mediated gene expression.
Gene Therapy and ACH-2 cells are similar to latent infection of cells in vivo. To test the effect of antitat on activation of latent proviruses, chronically infected U1 and ACH-2 cells were transduced with the antitat retroviral vector or a control vector and then exposed to TNF-␣, a cytokine known to induce HIV-1 replication in these cells, plus PMA. Our data indicate that chronically infected T-lymphocytic and monocytic cells transduced with antitat retroviral vector were highly resistant to TNF-␣ plus PMA-induced HIV-1 expression compared with the same cells transduced with control vector. In addition, we examined the antiviral activity of antitat on in vivo established infection. Peripheral blood mononuclear cells isolated from patients with HIV-1 infection were transduced with antitat vector. In the absence of G418 cell selection, the antitat gene blocked HIV-1 gag gene expression and allowed PBMC from HIV-1 infected subjects to expand in culture. To determine whether PBMC expansion was due to specific inhibition of HIV-1-induced cell death rather than some nonspecific effects of the antitat gene, PBMC isolated from healthy donors were transduced with antitat and control vectors. No expansion occurred in the antitat transduced PBMC compared with the controls, as demonstrated by CD4 expression on T lymphocytes (data not shown). These data suggest that antitat gene not only inhibits HIV-1 laboratory strains in chronically infected promonocytic and T cell lines but also prevents CD4 + cell death in primary PBMC isolated from HIV-infected patients. Via this mechanism, antitat gene therapy might also contribute to reconstitution of the immune system of patients with HIV-1 infection or AIDS.
G418 selection of antitat retroviral transduced U1 and ACH-2 cells was required to obtain significant inhibition of HIV-1 replication, suggesting that transduction efficiency of U1 and ACH-2 cells with retroviral vectors was low. In fact, expression of neo-R gene was detected in only 20-30% of non-selected cells. Although antitat retroviral vector-transduced and G418-selected U1 and ACH-2 cells were used for this study, complete inhibition of HIV-1 replication in these cells was not observed. This phenomenon could be due to differential expression of antitat in cells, caused by random integration of MLV into cellular DNA. Supporting this hypothesis, neo-R gene expression was detected in about 80% of G418-selected U1 and ACH-2 cells (Figure 2) . Thus, protective levels of antitat may have been achieved in only a portion of the transduced cells. Improved efficiency of transduction of U1 and ACH-2 cells might protect greater numbers of cells against HIV-1 replication without the need for G418 selection. Importantly, the protective effects were noted after multiple passages of U1 and ACH-2 cells transduced with antitat retroviral vector. Even after 5 months of maintenance in G418-free media, cells transduced with antitat-containing vector were still highly resistant to TNF-␣-plus PMA-induced HIV-1 replication compared with cells transduced by control vector. These results demonstrate that antitat gene introduced into chronically infected U1 and ACH-2 cells is maintained in daughter cells.
Taken together, our studies provide experimental evidence that antitat gene therapy inhibits HIV-1 gene expression and replication in previously infected cells. Based on these data, antitat gene therapy continues to be a promising approach for control of HIV-1 replication in HIV-infected individuals.
Materials and methods
Cell cultures HIV-1-infected U1 and ACH-2 cell lines were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institutes of Health. U1 is a cloned cell-line derived by limiting dilution cloning of U937 cells surviving an acute infection with HIV-1 (LAV-1 strain). U1 cells are characterized by the presence of two copies of integrated HIV-1 proviral DNA per cell. 20, 21 Virus expression in U1 cells is constitutively low as determined by HIV-1 reverse transcriptase (RT), p24 antigen, Western blot and Northern blot assays. 20, 21 ACH-2 is a cloned cell-line derived from a human T cell line that survived acute HIV-1 infection. Restriction enzyme analysis indicated the presence of a single integrated copy of proviral DNA. ACH-2 cells constitutively produce low levels of HIV-1 RT. 22 Most ACH-2 cells have no detectable HIV-1 RNA, but 2% have high levels of HIV-1 RNA.
22 U1 and ACH-2 cells were cultured in RPMI 1640 (Gibco Laboratories, Grand Island, NY, USA) supplemented with 2 mm glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 10% (v/v) heat-inactivated fetal calf serum (FCS, Hyclone Laboratories, Logan, UT, USA). Cell viability was assessed using trypan blue dye exclusion. As demonstrated by limulus amebocyte lysate assay, all media and reagents used were endotoxin-free.
Retroviral vectors and packaging lines
The construction of the antitat retrovirus vector was described in detail previously. 13, 18 PA317, a retroviral packaging cell line, was obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco Laboratories) with 10% FCS. Subconfluent PA317 cells were transfected with 10 g of retroviral expression plasmids with or without antitat gene, 13, 18 using a standard calcium-phosphate method (Promega, Madison, WI, USA), according to the manufacturer's instructions. After the transfected cells were selected in 800 g/ml of Geneticin (G418, Gibco Laboratories) for 2 weeks, resistant colonies were pooled, and supernatants were collected. Virus titers were determined as described previously. 12, 24 The intracellular expression of the neomycin resistant (neo-R) gene in the retrovirus vectors was verified by RT-PCR.
Transduction of U1 and ACH-2 cells with antitat gene U1 or ACH-2 cells (2 × 10 6 cells) were co-cultured with PA317 amphotropic packaging cells that had been transfected with retroviral vector containing antitat gene and selected with G418. After 48 h, the transduced U1 and ACH-2 cells were maintained in G418 (800 g/ml)-containing media for 2 weeks. The G418-selected U1 and ACH-2 cells expressed mRNA of transduced neo-R gene as determined by RT-PCR assay. Control U1 and ACH-2 cells were transduced with control retroviral vector under identical conditions.
Transduction of PBMC with antitat gene PBMC were isolated by Ficoll-Hypaque density gradient centrifugation, stimulated with phytohemagglutinin (PHA, Difco, Detroit, MI, USA) and cultured in RPMI medium supplemented with 10% fetal calf serum and 100 U of interleukin-2 (Roche Molecular Biochemicals, Indianapolis, IN, USA) per milliliter. After 2 days, aliquots of PBMC (10 6 cells per ml) were cocultured with antitat PA317 cells (3 × 10 6 ) for 48 h and selected with G418 (250-500 g/ml) for 7 days. The PBMC were then incubated with TNF-␣ (R&D Systems, Minneapolis, MN, USA) (2 ng/ml) plus PMA (Sigma Chemical Co, St Louis, MO, USA) (2 ng/ml). Cells were then split into two portions: 2 × 10 6 cells were subjected to total RNA extraction followed by RT-PCR for HIV-1 gag gene expression 24 h after incubation with TNF-␣ plus PMA, while 1 × 10 6 cells were cultured for an additional 14 days to analyze CD4 antigen expression.
Induction of HIV-1 replication in transduced or nontransduced U1 or ACH-2 Antitat gene or control vector-transduced and G-418 selected U1 or ACH-2 cells (10 6 cells per well) in 24-well culture plates were incubated in triplicate with TNF-␣ (2 ng/ml) plus PMA (2 ng/ml). After 24 h of incubation at 37°C in 5% CO 2 , the cells in one well were collected for isolation of total RNA and then subjected to RT-PCR assay for HIV gag gene expression. The culture supernatants in the remaining two wells were harvested for HIV-1 RT activity at different time-points.
HIV-1 RT assay HIV-1 RT activity was determined based on the technique of Willey et al 29 with modification. Briefly, 10 l of culture supernatants were added to a cocktail containing poly (A), oligo (dT) (Pharmacia, Piscataway, NJ, USA), MgCl 2 and 32p dTTP (Amersham, Arlington Heights, IL, USA) and incubated for 20 h at 37°C. Then 30 l of the cocktail were spotted on to DE81 paper, dried and washed five times with 2 × saline-sodium citrate buffer (SSC) and once with 95% ethanol. The filter was then airdried. Radioactivity was counted in a liquid scintillation counter (Packard Instruments, Palo Alto, CA, USA).
RNA extraction
Total RNA was extracted from U1 or ACH-2 cells (3 × 10 6 ) using Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA). Briefly, the total RNA was extracted by the single step, acid guanidium thiocyanatephenol-chloroform method. After centrifugation at 13 000 g for 15 min, the RNA-containing aqueous phase was precipitated in isopropanol. RNA precipitates were washed once in 75% ethanol and resuspended in 50 l of RNAse-free water.
DNA extraction
Cells were lysed in a buffer containing 100 mm KCl, 20 mm Tris, pH 8.4, 500 g/ml proteinase K (BDH, Poole, UK), and 0.2% (v/v) NP-40 (BDH). Lysates were incubated at 60°C for 2 h followed by 100°C for 15 min.
Reverse transcriptase-initiated polymerase chain reaction (RT-PCR) analysis To measure mRNA expression for neo-R or HIV-1 gag, total RNA (1 g) extracted from U1 or ACH-2 cells was reversibly transcribed using the Reverse Transcription System (Promega) with specific primers for neo-R gene or HIV-1 gag gene (antisense) for 1 h at 42°C. The reaction was terminated by incubating the reaction mixture at 99°C for 5 min. The resulting cDNA was used as a template for PCR amplification. PCR amplification was performed with one tenth of the cDNA for 40 cycles with AmpliTaqGold (Perkin Elmer-Cetus, Foster City, CA, USA) in a GeneAmp PCR System 2400 (Perkin ElmerCetus). The PCR reaction mixture contained 0.2 mm of dNTPs, 20 pm of each of two primers and 1.5 unit of AmpliTaqGold in 1 × reaction buffer (Perkin ElmerCetus). Each of PCR amplifications consisted of heat activation of AmpliTaqGold for 9 min at 94°C, followed by 40 cycles of 94°C for 30 s, 50°C for 30 s and 72°C for 45 s using the specific oligonucleotide primers as follows: neo-R gene primers: 5′-TGAAGAGCTTGGCGGCGA ATG-3′ (sense) and 3′-GGCGAAGAACTCCAGCAT GAG-5′ (antisense); HIV-1 gag gene primers: 5′-GGTA CATCAGGCCATATCACC-3′ (sense) and 5′-TGACA TGCTGTCATCATTTCTTC-3′ (antisense). For amplification of HIV-1 gag gene in PBMC isolated from patients with HIV-1 infection, we used SK38/39 primers: 5′-ATAATCCACCTATCCCAGTAGGAGAAAT-3′ (sense) and 5′-TTTGGTCCTTGTCTTATGTCCAGAATGC-3′ (antisense). ␤-Actin primers: 5′-ATGTGGCACCACAC CTTCTACAATGAGCTGCG-3′ (sense) and 5′-CGTCAT ACTCCTGCTTGCTGATCCACATCTGC-3′ (antisense). ␤-Actin was used as a housekeeping gene control. The oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). RT-PCRamplified products were analyzed by 2% agarose gel electrophoresis. Electronics, Hialeah, FL, USA) using Elite software. Fluorescein-conjugated anti-CD4 mAb (OKT4A) and fluorescein-conjugated mouse IgG1 were purchased from R&D Systems (Minneapolis, MN, USA).
Statistical analysis
The data were analyzed using the Student's t test for paired samples.
